- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04163250
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
Prognostic Value of Urinary TIMP-2/ IGFBP7 in Intra-Arterial Contrast-Associated Acute Kidney Injury
Radiological examinations that require the administration of iodinated contrasts (IC) for diagnostic and therapeutic purposes are essential in current clinical practice, and their use in interventional procedures has been progressively increasing.
IC can cause kidney damage, so there is caution in their use in at-risk populations. This fact may limit its diagnostic use, with data on underutilization of interventional techniques in patients with renal insufficiency, which worsen their prognosis.
In addition, once the use of IC contrasts is decided, preventive measures, such as hyperhydration,are used and can have potential side effects, especially in patients at risk of heart failure (acute coronary syndrome, low left ventricular ejection fraction).
New biomarkers of kidney damage have recently been developed, based on the detection of molecules expressed by the kidney in situations of early damage. The quantitative determination of cell cycle arrest proteins (Tissue Inhibitor of metalloproteinase 2 (TIMP2) and Insulin-Like Growth Factor Binding Protein -7 (IGFBP7)) can be predictive of the development of moderate to severe contrast-associated acute kidney injury.
Urinary determination of [TIMP-2] x [IGFBP7] in patients with ACS (acute coronary syndromes) before cardiac catheterization would allow early identification of those patients vulnerable to IC-induced toxicity and adjustment of preventive measures.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Urinary determination of [TIMP-2] x [IGFBP7] in patients with ACS undergoing cardiac catheterization would allow early identification of those patients vulnerable to IC-induced toxicity and adjustment of both appropriate preventive measures.
A prospective, descriptive observational study will be carried out to determine sensitivity and specificity of the urinary determination of TIMP2-IGFBP7 and predictive values in the early diagnosis of contrast-associated acute kidney injury (AKI) in patients admitted to the Coronary Care Unit (CCU) in a spanish hospital.
OBJECTIVES
- PRIMARY OBJECTIVE: To determine the operational characteristics (sensitivity, specificity) of the TIMP2-IGFBP7 biomarker in routine clinical practice, in the early diagnosis of contrast-induced AKI (acute renal injury) in patients admitted to the CCU, exposed to iodinated contrasts. The established renal failure is defined as KDIGO (Kidney Disease Improving Global Outcomes) stage ≥ 2 in the 24 to 72 hours after the administration of contrasts.
- SECONDARY OBJECTIVES
Evaluate these parameters according to the patient's initial risk level:
- Estimated renal function upon admission
- Initial severity estimated by GRACE score
- Sex
- Age
- Contrast media type and volume
- Patient weight
- Dose of contrast
- Diabetes
A single determination (10 ml of fresh urine) should be collected in a sterile container and the laboratory should centrifuge them within the time of collection. Neither the attending physicians nor the investigators will know the results, and the treatment will not be influenced.
The result is reported as a single value which is the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without any unit or concentrations of individual biomarkers. As previously reported, a value of> 0.3 identifies patients with a high probability of presenting a moderate to severe AKI (acute kidney injury) in 12 hours, while a value of ≤ 0.3 identifies patients with a low risk of developing a moderate to serious AKI
An aliquot of urine will be stored at -80 ° C in the Clinical Analysis Department
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alicante
-
Elche, Alicante, Spain, 03203
- Hospital General Universitario de Elche
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients older than 21 years exposed to intra-arterial iodinated contrast media for diagnostic / therapeutic purposes and who have signed the Informed Consent document.
Exclusion Criteria:
- Patients who have been exposed to a previous dose of iodinated contrast within 72 hours prior to recruitment.
- Patients with urgent radiodiagnostic intervention criteria, when it is not possible to obtain a previous urine sample without delaying the diagnosis and / or the intervention.
- Patients in anuria.
- Patients with chronic kidney disease, treated with hemodialysis (HD) or peritoneal dialysis.
- Bilirubinuria: bilirubin concentrations in the urine> 7.2 g / dL interfere with the result.
- Patients in terminal situations, in which diagnostic and therapeutic tests are limited.
- Patients under 21 years.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with ACS undergoing cardiac catheterization
Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention. The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes |
Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result. According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection. The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Contrast-Associated Acute Kidney Injury
Time Frame: up to 72 hours of exposure
|
Absolute increase of 0.3 mg / dl in the creatinine value and / or a relative increase greater than 1.5 times the baseline creatinine value, measured at 48 and 72 hours after exposure to contrast.
|
up to 72 hours of exposure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: up to 30 days
|
Patients who die during their hospital stay for any reason
|
up to 30 days
|
Need of renal replacement techniques
Time Frame: From exposure to contrasts to three months
|
Hemodialysis, peritoneal dialysis or continuous renal replacement techniques,
|
From exposure to contrasts to three months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GV/2019/003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast-induced Nephropathy
-
Singapore General HospitalActive, not recruitingContrast-induced NephropathySingapore
-
Chinese PLA General HospitalUnknownContrast-induced NephropathyChina
-
Memorial University of NewfoundlandUniversity of AlbertaWithdrawnContrast Induced NephropathyCanada
-
Sun Yat-sen UniversityCompletedContrast Induced NephropathyChina
-
Isfahan University of Medical SciencesUnknownContrast-Induced NephropathyIran, Islamic Republic of
-
Mt. Sinai Medical Center, MiamiFlorida Heart Research InstituteCompleted
-
Kaiser PermanenteCompletedKidney Diseases | Contrast Induced NephropathyUnited States
-
Ospedale Misericordia e DolceCompletedContrast Induced NephropathyItaly
-
Guangdong Provincial People's HospitalGuangdong Medical College; Hainan People's HospitalUnknownContrast Induced NephropathyChina
-
University of ThessalyUnknownContrast Induced Nephropathy
Clinical Trials on Urinary determination of TIMP-2/ IGFBP7
-
Instituto Nacional de Enfermedades RespiratoriasUnknownCoronavirus Infection | Covid19 | AKI | SARS (Severe Acute Respiratory Syndrome)Mexico
-
Policlinico HospitalRecruitingAcute Kidney InjuryItaly
-
Royal Surrey County Hospital NHS Foundation TrustCompletedAcute Kidney InjuryUnited Kingdom
-
Centre Hospitalier Universitaire, AmiensCompletedHeart Failure | Renal FailureFrance
-
Universitat Jaume ICompleted
-
Ruhr University of BochumRecruitingVentricular Fibrillation | Heart Arrest | Ventricular Tachycardia | Ventricular FlutterGermany
-
Central Hospital, Nancy, FranceCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
University of Alabama at BirminghamNot yet recruitingObesity | Weight LossUnited States
-
Astex Pharmaceuticals, Inc.CompletedMyelodysplastic SyndromeUnited States